Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

Jason Mast

Editor

It won’t get quite the work-on-Thanksgiving welcome that the Covid-19 jab received, but another Pfizer vaccine is headed to the FDA, where it will receive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

Jason Mast

Editor

Sign up to read this article for free.

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Senior AstraZeneca exec detained in China amid wider investigation

Genmab chops early cancer prospects to prioritize Phase 3 projects

Denali teases early data for enzyme replacement therapy in rare disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Beat­ing Mer­ck, Pfiz­er gets pri­or­i­ty re­view as the first Pre­vnar fol­low-up heads to the FDA

Jason Mast

Editor

Sign up to read this article for free.

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Gen­mab chops ear­ly can­cer prospects to pri­or­i­tize Phase 3 projects

De­nali teas­es ear­ly da­ta for en­zyme re­place­ment ther­a­py in rare dis­ease

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Senior AstraZeneca exec detained in China amid wider investigation

Genmab chops early cancer prospects to prioritize Phase 3 projects

Denali teases early data for enzyme replacement therapy in rare disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks